TY - JOUR
T1 - Phenotypic and functional characterization of nk cells in αβt-cell and b-cell depleted haplo-hsct to cure pediatric patients with acute leukemia
AU - Meazza, R.
AU - Falco, M.
AU - Loiacono, F.
AU - Canevali, P.
AU - Chiesa, M. D.
AU - Bertaina, A.
AU - Pagliara, D.
AU - Merli, P.
AU - Indio, V.
AU - Galaverna, F.
AU - Algeri, M.
AU - Moretta, F.
AU - Colomar-Carando, N.
AU - Muccio, L.
AU - Sivori, S.
AU - Pession, A.
AU - Mingari, M. C.
AU - Moretta, L.
AU - Moretta, A.
AU - Locatelli, Franco
AU - Pende, D.
PY - 2020
Y1 - 2020
N2 - NK cells can exert remarkable graft-versus-leukemia (GvL) effect in HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Here, we dissected the NK-cell repertoire of 80 pediatric acute leukemia patients previously reported to have an excellent clinical outcome after αβT/B-depleted haplo-HSCT. This graft manipulation strategy allows the co-infusion of mature immune cells, mainly NK and γδT cells, and hematopoietic stem cells (HSCs). To promote NK-cell based antileukemia activity, 36/80 patients were transplanted with an NK alloreactive donor, defined according to the KIR/KIR-Ligand mismatch in the graft-versus-host direction. The analysis of the reconstituted NK-cell repertoire in these patients showed relatively high proportions of mature and functional KIR+NKG2A−CD57+ NK cells, including the alloreactive NK cell subset, one month after HSCT. Thus, the NK cells adoptively transfused with the graft persist as a mature source of effector cells while new NK cells differentiate from the donor HSCs. Notably, the alloreactive NK cell subset was endowed with the highest anti-leukemia activity and its size in the reconstituted repertoire could be influenced by human cytomegalovirus (HCMV) reactivation. While the phenotypic pattern of donor NK cells did not impact on post-transplant HCMV reactivation, in the recipients, HCMV infection/reactivation fostered a more differentiated NK-cell phenotype. In this cohort, no significant correlation between differentiated NK cells and relapse-free survival was observed.
AB - NK cells can exert remarkable graft-versus-leukemia (GvL) effect in HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Here, we dissected the NK-cell repertoire of 80 pediatric acute leukemia patients previously reported to have an excellent clinical outcome after αβT/B-depleted haplo-HSCT. This graft manipulation strategy allows the co-infusion of mature immune cells, mainly NK and γδT cells, and hematopoietic stem cells (HSCs). To promote NK-cell based antileukemia activity, 36/80 patients were transplanted with an NK alloreactive donor, defined according to the KIR/KIR-Ligand mismatch in the graft-versus-host direction. The analysis of the reconstituted NK-cell repertoire in these patients showed relatively high proportions of mature and functional KIR+NKG2A−CD57+ NK cells, including the alloreactive NK cell subset, one month after HSCT. Thus, the NK cells adoptively transfused with the graft persist as a mature source of effector cells while new NK cells differentiate from the donor HSCs. Notably, the alloreactive NK cell subset was endowed with the highest anti-leukemia activity and its size in the reconstituted repertoire could be influenced by human cytomegalovirus (HCMV) reactivation. While the phenotypic pattern of donor NK cells did not impact on post-transplant HCMV reactivation, in the recipients, HCMV infection/reactivation fostered a more differentiated NK-cell phenotype. In this cohort, no significant correlation between differentiated NK cells and relapse-free survival was observed.
KW - Haploidentical hematopoietic stem cell transplantation (HSCT)
KW - Human cytomegalovirus (HCMV)
KW - Killer Ig-like receptors (KIR)
KW - NK alloreactivity
KW - NK cells
KW - Pediatric acute leukemia
KW - Haploidentical hematopoietic stem cell transplantation (HSCT)
KW - Human cytomegalovirus (HCMV)
KW - Killer Ig-like receptors (KIR)
KW - NK alloreactivity
KW - NK cells
KW - Pediatric acute leukemia
UR - https://publicatt.unicatt.it/handle/10807/229744
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85089407211&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089407211&origin=inward
U2 - 10.3390/cancers12082187
DO - 10.3390/cancers12082187
M3 - Article
SN - 2072-6694
VL - 12
SP - 1
EP - 21
JO - Cancers
JF - Cancers
IS - 8
ER -